PTCT
PTC Therapeutics, Inc.
Price Chart
Latest Quote
$78.98
+0.45 (+0.57%)
Current Price
| Previous Close | $78.53 |
| Open | $79.58 |
| Day High | $80.00 |
| Day Low | $78.10 |
| Volume | 2,870,286 |
Stock Information
| Shares Outstanding | 82.95M |
| Total Debt | $2.72B |
| Cash Equivalents | $1.89B |
| Revenue | $827.11M |
| Net Income | $-186.73M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $6.55B |
| EPS (TTM) | $-2.54 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $7.38B |
| Sales | $827.11M |
| Income | $-186.73M |
| Book/sh | $-2.52 |
| Cash/sh | $22.81 |
| Employees | 991 |
Financial Ratios
| Quick Ratio | 2.29 |
| Current Ratio | 2.44 |
Returns & Margins
| ROA | -1.54% |
| Gross Margin | 38.32% |
| Operating Margin | 16.54% |
| Profit Margin | -22.58% |
Ownership
| Insider Ownership | 7.38% |
| Institutional Ownership | 117.65% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 28.38 |
| P/S | 7.92 |
| P/B | -31.34 |
Analyst Data
| Recommendation | buy |
| Target Price | $93.93 |
Technical Indicators
| SMA20 | $72.47 |
| SMA50 | $71.02 |
| SMA200 | $70.29 |
| RSI | 60.59 |
| ATR | 3.3209 |
| Shares Float | 73.17M |
| Short Float | 17.48% |
| Short Ratio | 7.05 |
| Volatility | 0.55 |
| Rel Volume | 1.64 |
Performance History
| Week | +5.72% |
| Month | +12.33% |
| Quarter | +17.75% |
| 6 Months | +4.72% |
| YTD | +2.92% |
| Year | +55.32% |
| 3 Years | +79.21% |
| 5 Years | +83.89% |
| 10 Years | +1031.52% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $78.98 | 2,870,300 |
| 2026-06-17 | $78.53 | 3,183,600 |
| 2026-06-16 | $73.27 | 6,044,200 |
| 2026-06-15 | $76.77 | 3,590,700 |
| 2026-06-12 | $75.14 | 1,074,600 |
| 2026-06-11 | $74.71 | 2,245,400 |
| 2026-06-10 | $73.35 | 1,211,400 |
| 2026-06-09 | $73.68 | 1,873,800 |
| 2026-06-08 | $70.87 | 1,293,400 |
| 2026-06-05 | $70.97 | 937,100 |
| 2026-06-04 | $70.64 | 1,098,000 |
| 2026-06-03 | $68.68 | 1,124,900 |
| 2026-06-02 | $68.23 | 1,238,400 |
| 2026-06-01 | $73.80 | 1,135,200 |
| 2026-05-29 | $73.85 | 1,211,000 |
| 2026-05-28 | $71.05 | 725,100 |
| 2026-05-27 | $70.66 | 1,692,400 |
| 2026-05-26 | $67.65 | 1,003,600 |
| 2026-05-22 | $68.81 | 715,100 |
| 2026-05-21 | $69.79 | 808,800 |
| 2026-05-20 | $71.02 | 1,093,400 |
| 2026-05-19 | $70.31 | 725,200 |
About PTC Therapeutics, Inc.
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.
đ° Latest News
PTC Therapeutics (PTCT) Moves 7.2% Higher: Will This Strength Last?
Zacks âĸ 2026-06-18T12:16:00Z
This Biotech Stock Is Surging 81% on Surprise Good News From FDA
Barrons.com âĸ 2026-06-17T19:33:00Z
Street Calls of the Week
Investing.com âĸ 2026-06-14T10:30:02ZSector Update: Healthcare Stocks Rise Late Afternoon
MT Newswires âĸ 2026-06-09T19:43:38ZToll Brothers upgraded, Lennar downgraded: Wall Street's top analyst calls
The Fly âĸ 2026-06-09T13:32:55Z
Why The PTC Therapeutics (PTCT) Story Is Shifting As Sephience Assumptions Drive New Valuations
Simply Wall St. âĸ 2026-06-07T12:06:53Z
Why This Fund Made a $189 Million Bet on Erasca as Shares Skyrocket 800%
Motley Fool âĸ 2026-05-30T00:47:22Z
Tango Therapeutics Stock Is Up 840%, and This Fund Just Disclosed Buying $164 Million More
Motley Fool âĸ 2026-05-30T00:41:49Z
KROS Turns to Next Wave of TGF-Beta Muscle Therapies
Zacks âĸ 2026-05-22T15:10:00Z
Should You Buy KROS After Q1 Miss and Takeda Deal Reset?
Zacks âĸ 2026-05-22T15:06:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $32,940,000 | $42,473,000 | $51,531,000 | $32,396,000 |
| Cost Of Revenue | $47,013,000 | $57,398,000 | $65,486,000 | $44,678,000 |
| Total Revenue | $1,730,655,000 | $806,780,000 | $937,822,000 | $698,801,000 |
| Operating Revenue | $1,730,655,000 | $806,780,000 | $937,822,000 | $698,801,000 |
| Expenses | ||||
| Interest Expense | $152,230,000 | $166,993,000 | $129,180,000 | $90,871,000 |
| Total Expenses | $874,147,000 | $953,527,000 | $1,287,224,000 | $1,138,726,000 |
| Other Income Expense | $-7,659,000 | $-49,379,000 | $-217,528,000 | $-56,691,000 |
| Other Non Operating Income Expenses | $-18,086,000 | $106,444,000 | $10,130,000 | $-49,207,000 |
| Net Non Operating Interest Income Expense | $-152,230,000 | $-166,993,000 | $-129,180,000 | $-90,871,000 |
| Interest Expense Non Operating | $152,230,000 | $166,993,000 | $129,180,000 | $90,871,000 |
| Operating Expense | $827,134,000 | $896,129,000 | $1,221,738,000 | $1,094,048,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $682,644,000 | $-363,295,000 | $-626,604,000 | $-559,017,000 |
| Net Interest Income | $-152,230,000 | $-166,993,000 | $-129,180,000 | $-90,871,000 |
| Normalized Income | $672,426,583 | $-240,194,830 | $-421,711,800 | $-551,895,226 |
| Net Income From Continuing And Discontinued Operation | $682,644,000 | $-363,295,000 | $-626,604,000 | $-559,017,000 |
| Total Operating Income As Reported | $866,935,000 | $-302,570,000 | $-439,502,000 | $-447,409,000 |
| Net Income Common Stockholders | $682,644,000 | $-363,295,000 | $-626,604,000 | $-559,017,000 |
| Net Income | $682,644,000 | $-363,295,000 | $-626,604,000 | $-559,017,000 |
| Net Income Including Noncontrolling Interests | $682,644,000 | $-363,295,000 | $-626,604,000 | $-559,017,000 |
| Net Income Continuous Operations | $682,644,000 | $-363,295,000 | $-626,604,000 | $-559,017,000 |
| Pretax Income | $696,619,000 | $-363,119,000 | $-696,110,000 | $-587,487,000 |
| Special Income Charges | $10,427,000 | $-155,823,000 | $-227,658,000 | $-7,484,000 |
| Operating Income | $856,508,000 | $-146,747,000 | $-349,402,000 | $-439,925,000 |
| Depreciation Amortization Depletion Income Statement | $24,742,000 | $60,738,000 | $222,635,000 | $116,554,000 |
| Depreciation And Amortization In Income Statement | $24,742,000 | $60,738,000 | $222,635,000 | $116,554,000 |
| Amortization Of Intangibles Income Statement | $24,742,000 | $60,738,000 | $222,635,000 | $116,554,000 |
| Gross Profit | $1,683,642,000 | $749,382,000 | $872,336,000 | $654,123,000 |
| Per Share | ||||
| Diluted EPS | $7.78 | $-4.73 | $-8.37 | $-7.79 |
| Basic EPS | $8.58 | $-4.73 | $-8.37 | $-7.79 |
| Other | ||||
| Tax Effect Of Unusual Items | $209,583 | $-32,722,830 | $-22,765,800 | $-362,226 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $877,237,000 | $35,360,000 | $-102,682,000 | $-360,296,000 |
| Total Unusual Items | $10,427,000 | $-155,823,000 | $-227,658,000 | $-7,484,000 |
| Total Unusual Items Excluding Goodwill | $10,427,000 | $-155,823,000 | $-227,658,000 | $-7,484,000 |
| Reconciled Depreciation | $38,815,000 | $75,663,000 | $236,590,000 | $128,836,000 |
| EBITDA (Bullshit earnings) | $887,664,000 | $-120,463,000 | $-330,340,000 | $-367,780,000 |
| EBIT | $848,849,000 | $-196,126,000 | $-566,930,000 | $-496,616,000 |
| Diluted Average Shares | $88,311,494 | $76,845,055 | $74,838,292 | $71,728,634 |
| Basic Average Shares | $79,534,290 | $76,845,055 | $74,838,292 | $71,728,634 |
| Diluted NI Availto Com Stockholders | $682,644,000 | $-363,295,000 | $-626,604,000 | $-559,017,000 |
| Tax Provision | $13,975,000 | $176,000 | $-69,506,000 | $-28,470,000 |
| Impairment Of Capital Assets | $-9,627,000 | $160,298,000 | $217,800,000 | $33,384,000 |
| Restructuring And Mergern Acquisition | $-800,000 | $-4,475,000 | $-127,700,000 | $-25,900,000 |
| Amortization | $24,742,000 | $60,738,000 | $222,635,000 | $116,554,000 |
| Research And Development | $455,249,000 | $534,480,000 | $666,563,000 | $651,496,000 |
| Selling General And Administration | $347,143,000 | $300,911,000 | $332,540,000 | $325,998,000 |
| Other Special Charges | - | - | $137,558,000 | - |
Fetched: 2026-06-21
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-676,407,000 | $-1,299,206,000 | $-1,280,393,000 | $-1,135,318,000 |
| Total Assets | $2,898,767,000 | $1,705,024,000 | $1,895,698,000 | $1,705,619,000 |
| Total Non Current Assets | $624,819,000 | $339,493,000 | $677,069,000 | $1,011,834,000 |
| Other Non Current Assets | $18,301,000 | $20,703,000 | $36,246,000 | $48,582,000 |
| Goodwill And Other Intangible Assets | $471,094,000 | $201,135,000 | $461,838,000 | $788,232,000 |
| Other Intangible Assets | $388,753,000 | $118,794,000 | $379,497,000 | $705,891,000 |
| Current Assets | $2,273,948,000 | $1,365,531,000 | $1,218,629,000 | $693,785,000 |
| Other Current Assets | $67,309,000 | $44,087,000 | $150,491,000 | $105,658,000 |
| Inventory | $79,647,000 | $23,194,000 | $30,577,000 | $21,808,000 |
| Receivables | $181,621,000 | $158,554,000 | $160,822,000 | $155,614,000 |
| Accounts Receivable | $181,621,000 | $158,554,000 | $160,822,000 | $155,614,000 |
| Allowance For Doubtful Accounts Receivable | $-15,200,000 | $-2,300,000 | $-1,200,000 | $-300,000 |
| Gross Accounts Receivable | $196,821,000 | $160,854,000 | $162,022,000 | $155,914,000 |
| Cash Cash Equivalents And Short Term Investments | $1,945,371,000 | $1,139,696,000 | $876,739,000 | $410,705,000 |
| Cash And Cash Equivalents | $984,648,000 | $779,709,000 | $594,001,000 | $279,834,000 |
| Non Current Prepaid Assets | - | - | - | - |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Net Debt | $1,610,349,000 | $1,587,479,000 | $1,504,309,000 | $1,049,774,000 |
| Total Debt | $2,707,064,000 | $2,471,072,000 | $2,229,123,000 | $1,461,513,000 |
| Long Term Debt And Capital Lease Obligation | $2,121,949,000 | $2,199,888,000 | $2,018,807,000 | $1,376,994,000 |
| Long Term Debt | $2,025,366,000 | $2,109,367,000 | $1,903,996,000 | $1,257,459,000 |
| Current Debt And Capital Lease Obligation | $585,115,000 | $271,184,000 | $210,316,000 | $84,519,000 |
| Current Debt | $569,631,000 | $257,821,000 | $194,314,000 | $72,149,000 |
| Other Current Borrowings | $569,631,000 | $257,821,000 | $194,314,000 | $72,149,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $3,104,080,000 | $2,803,095,000 | $2,714,253,000 | $2,052,705,000 |
| Total Non Current Liabilities Net Minority Interest | $2,135,653,000 | $2,222,114,000 | $2,111,153,000 | $1,646,469,000 |
| Other Non Current Liabilities | $13,704,000 | $21,426,000 | $141,000 | $2,641,000 |
| Tradeand Other Payables Non Current | $0 | $800,000 | $36,300,000 | $164,000,000 |
| Current Liabilities | $968,427,000 | $580,981,000 | $603,100,000 | $406,236,000 |
| Current Deferred Liabilities | $2,040,000 | $5,505,000 | $801,000 | $1,351,000 |
| Payables And Accrued Expenses | $178,338,000 | $184,073,000 | $252,164,000 | $193,910,000 |
| Payables | $50,580,000 | $33,000,000 | $8,545,000 | $31,980,000 |
| Other Payable | $416,000 | $11,025,000 | $2,500,000 | - |
| Total Tax Payable | $4,677,000 | $4,701,000 | $0 | $4,712,000 |
| Income Tax Payable | $4,677,000 | $4,701,000 | $0 | $4,712,000 |
| Accounts Payable | $45,487,000 | $17,274,000 | $6,045,000 | $27,268,000 |
| Non Current Deferred Liabilities | - | $0 | $55,905,000 | $102,834,000 |
| Non Current Deferred Taxes Liabilities | - | $0 | $55,905,000 | $102,834,000 |
| Other Current Liabilities | - | - | - | $72,149,000 |
| Equity | ||||
| Common Stock Equity | $-205,313,000 | $-1,098,071,000 | $-818,555,000 | $-347,086,000 |
| Total Equity Gross Minority Interest | $-205,313,000 | $-1,098,071,000 | $-818,555,000 | $-347,086,000 |
| Stockholders Equity | $-205,313,000 | $-1,098,071,000 | $-818,555,000 | $-347,086,000 |
| Gains Losses Not Affecting Retained Earnings | $10,501,000 | $-25,886,000 | $-1,285,000 | $4,796,000 |
| Other Equity Adjustments | $10,501,000 | $-25,886,000 | $-1,285,000 | $4,796,000 |
| Retained Earnings | $-2,964,229,000 | $-3,646,873,000 | $-3,283,578,000 | $-2,656,974,000 |
| Other | ||||
| Ordinary Shares Number | $81,474,366 | $77,704,188 | $75,708,889 | $73,104,692 |
| Share Issued | $81,474,366 | $77,704,188 | $75,708,889 | $73,104,692 |
| Tangible Book Value | $-676,407,000 | $-1,299,206,000 | $-1,280,393,000 | $-1,135,318,000 |
| Invested Capital | $2,389,684,000 | $1,269,117,000 | $1,279,755,000 | $982,522,000 |
| Working Capital | $1,305,521,000 | $784,550,000 | $615,529,000 | $287,549,000 |
| Capital Lease Obligations | $112,067,000 | $103,884,000 | $130,813,000 | $131,905,000 |
| Total Capitalization | $1,820,053,000 | $1,011,296,000 | $1,085,441,000 | $910,373,000 |
| Additional Paid In Capital | $2,748,335,000 | $2,574,611,000 | $2,466,233,000 | $2,305,020,000 |
| Capital Stock | $80,000 | $77,000 | $75,000 | $72,000 |
| Common Stock | $80,000 | $77,000 | $75,000 | $72,000 |
| Long Term Capital Lease Obligation | $96,583,000 | $90,521,000 | $114,811,000 | $119,535,000 |
| Current Deferred Revenue | $2,040,000 | $5,505,000 | $801,000 | $1,351,000 |
| Current Capital Lease Obligation | $15,484,000 | $13,363,000 | $16,002,000 | $12,370,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $73,737,000 | $61,575,000 | $62,643,000 | $62,669,000 |
| Current Provisions | $129,197,000 | $58,644,000 | $77,176,000 | $63,787,000 |
| Current Accrued Expenses | $127,758,000 | $151,073,000 | $243,619,000 | $161,930,000 |
| Goodwill | $82,341,000 | $82,341,000 | $82,341,000 | $82,341,000 |
| Net PPE | $135,424,000 | $117,655,000 | $178,985,000 | $175,020,000 |
| Accumulated Depreciation | $-46,993,000 | $-33,358,000 | $-51,274,000 | $-37,368,000 |
| Gross PPE | $182,417,000 | $151,013,000 | $230,259,000 | $212,388,000 |
| Leases | $35,161,000 | $31,531,000 | $30,166,000 | $28,969,000 |
| Construction In Progress | $2,803,000 | $3,034,000 | $24,008,000 | $14,349,000 |
| Other Properties | $80,053,000 | $56,685,000 | $91,896,000 | $102,430,000 |
| Machinery Furniture Equipment | $64,400,000 | $59,763,000 | $84,189,000 | $66,640,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $21,670,000 | $8,440,000 | $11,634,000 | $6,656,000 |
| Work In Process | $55,686,000 | $12,216,000 | $17,991,000 | $14,074,000 |
| Raw Materials | $2,291,000 | $2,538,000 | $952,000 | $1,078,000 |
| Other Short Term Investments | $960,723,000 | $359,987,000 | $282,738,000 | $130,871,000 |
Fetched: 2026-06-21
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $411,184,000 | $-181,937,000 | $-279,037,000 | $-509,114,000 |
| Operating Activities | ||||
| Operating Cash Flow | $711,196,000 | $-107,688,000 | $-158,418,000 | $-356,654,000 |
| Cash Flow From Continuing Operating Activities | $711,196,000 | $-107,688,000 | $-158,418,000 | $-356,654,000 |
| Operating Gains Losses | $10,754,000 | $-5,731,000 | $38,717,000 | $30,230,000 |
| Investing Activities | ||||
| Capital Expenditure | $-300,012,000 | $-74,249,000 | $-120,619,000 | $-152,460,000 |
| Investing Cash Flow | $-861,984,000 | $44,182,000 | $-176,737,000 | $290,181,000 |
| Cash Flow From Continuing Investing Activities | $-861,984,000 | $44,182,000 | $-176,737,000 | $290,181,000 |
| Net Other Investing Changes | - | $150,000,000 | - | - |
| Financing Activities | ||||
| Financing Cash Flow | $331,094,000 | $255,866,000 | $646,400,000 | $167,952,000 |
| Cash Flow From Continuing Financing Activities | $331,094,000 | $255,866,000 | $646,400,000 | $167,952,000 |
| Net Other Financing Charges | $233,659,000 | $223,592,000 | $917,785,000 | $-51,854,000 |
| Issuance Of Capital Stock | - | $0 | $0 | $50,000,000 |
| Net Common Stock Issuance | - | $0 | $0 | $50,000,000 |
| Common Stock Issuance | - | $0 | $0 | $50,000,000 |
| Other | ||||
| Repayment Of Debt | $-1,611,000 | $-1,490,000 | $-301,379,000 | $-151,276,000 |
| Interest Paid Supplemental Data | $5,702,000 | $5,823,000 | $36,131,000 | $18,463,000 |
| Income Tax Paid Supplemental Data | $36,854,000 | $17,550,000 | $14,155,000 | $4,922,000 |
| End Cash Position | $998,334,000 | $795,316,000 | $610,284,000 | $295,925,000 |
| Beginning Cash Position | $795,316,000 | $610,284,000 | $295,925,000 | $197,218,000 |
| Effect Of Exchange Rate Changes | $22,712,000 | $-7,328,000 | $3,114,000 | $-2,772,000 |
| Changes In Cash | $180,306,000 | $192,360,000 | $311,245,000 | $101,479,000 |
| Proceeds From Stock Option Exercised | $99,046,000 | $33,764,000 | $29,994,000 | $21,082,000 |
| Net Issuance Payments Of Debt | $-1,611,000 | $-1,490,000 | $-301,379,000 | $148,724,000 |
| Net Long Term Debt Issuance | $-1,611,000 | $-1,490,000 | $-301,379,000 | $148,724,000 |
| Long Term Debt Payments | $-1,611,000 | $-1,490,000 | $-301,379,000 | $-151,276,000 |
| Net Investment Purchase And Sale | $-562,042,000 | $-59,625,000 | $-56,118,000 | $442,641,000 |
| Sale Of Investment | $855,116,000 | $607,736,000 | $156,366,000 | $518,192,000 |
| Purchase Of Investment | $-1,417,158,000 | $-667,361,000 | $-212,484,000 | $-75,551,000 |
| Net Intangibles Purchase And Sale | $-291,152,000 | $-67,747,000 | $-92,181,000 | $-120,444,000 |
| Purchase Of Intangibles | $-291,152,000 | $-67,747,000 | $-92,181,000 | $-120,444,000 |
| Net PPE Purchase And Sale | $-8,790,000 | $21,554,000 | $-28,438,000 | $-32,016,000 |
| Sale Of PPE | $70,000 | $28,056,000 | $0 | $0 |
| Purchase Of PPE | $-8,860,000 | $-6,502,000 | $-28,438,000 | $-32,016,000 |
| Change In Working Capital | $-47,880,000 | $102,543,000 | $-4,003,000 | $-85,335,000 |
| Change In Other Working Capital | $-3,998,000 | $4,917,000 | $-550,000 | $1,351,000 |
| Change In Other Current Liabilities | $-17,396,000 | $11,830,000 | $-2,307,000 | $-4,558,000 |
| Change In Payables And Accrued Expense | $71,741,000 | $-33,322,000 | $48,346,000 | $27,542,000 |
| Change In Prepaid Assets | $-34,180,000 | $111,222,000 | $-39,770,000 | $-54,534,000 |
| Change In Inventory | $-53,896,000 | $6,164,000 | $-8,183,000 | $-6,668,000 |
| Change In Receivables | $-10,151,000 | $1,732,000 | $-1,539,000 | $-48,468,000 |
| Changes In Account Receivables | $-10,151,000 | $1,732,000 | $-1,539,000 | $-48,468,000 |
| Other Non Cash Items | $-20,983,000 | $-78,981,000 | $-104,670,000 | $186,000 |
| Stock Based Compensation | $74,547,000 | $74,615,000 | $131,206,000 | $110,333,000 |
| Unrealized Gain Loss On Investment Securities | $-9,694,000 | $-7,704,000 | $1,676,000 | $17,292,000 |
| Asset Impairment Charge | $1,018,000 | $163,643,000 | $217,800,000 | $33,384,000 |
| Amortization Of Securities | $-18,022,000 | $-12,529,000 | $-2,200,000 | $1,713,000 |
| Deferred Tax | $-3,000 | $-55,912,000 | $-46,930,000 | $-34,276,000 |
| Deferred Income Tax | $-3,000 | $-55,912,000 | $-46,930,000 | $-34,276,000 |
| Depreciation Amortization Depletion | $38,815,000 | $75,663,000 | $236,590,000 | $128,836,000 |
| Depreciation And Amortization | $38,815,000 | $75,663,000 | $236,590,000 | $128,836,000 |
| Gain Loss On Investment Securities | $7,081,000 | - | $-3,601,000 | - |
| Net Foreign Currency Exchange Gain Loss | $3,380,000 | $-10,374,000 | $-14,113,000 | $30,150,000 |
| Gain Loss On Sale Of PPE | $130,000 | $4,298,000 | $0 | $0 |
| Net Income From Continuing Operations | $682,644,000 | $-363,295,000 | $-626,604,000 | $-559,017,000 |
| Issuance Of Debt | - | $0 | $0 | $300,000,000 |
| Long Term Debt Issuance | - | $0 | $0 | $300,000,000 |
| Amortization Cash Flow | - | $60,700,000 | $222,600,000 | $116,600,000 |
| Amortization Of Intangibles | - | $60,700,000 | $222,600,000 | $116,600,000 |
| Depreciation | - | $14,900,000 | $13,900,000 | $12,300,000 |
Fetched: 2026-06-21